Skip to main content
⌘K
·
Launch Terminal
Launch Terminal
Home
SEC Filings
Home
SEC Filings
Filings
Filing Date
Form Type
Company
Description
AI
Link
Learn
MCP
API
Cookie Preferences
Material events
Financial results
Capital raises
Insider transactions
Fund filings
Advanced filters
Any time
Sort
Filings
Filing Date
Form Type
Company
Description
AI
Link
Browse AI-analysed SEC filings
Page 14 of 73 · 7,256 total
OSBC: 8-K · leadership change
OSBC · 8-K · 2026-10-19
KMX: 8-K · leadership change
KMX · 8-K · 2026-10-19
WHLR: 424B3 · prospectus supplement
WHLR · 424B3 · 2026-10-19
WRB: 8-K · earnings release
WRB · 8-K · 2026-10-19
WASH: 8-K · earnings release
WASH · 8-K · 2026-10-19
CRSP: 8-K · leadership change
CRSP · 8-K · 2026-10-19
WHLR: 424B3 · prospectus supplement
WHLR · 424B3 · 2026-10-19
CCK: 8-K · earnings release
CCK · 8-K · 2026-10-19
BOKF: 8-K · earnings release
BOKF · 8-K · 2026-10-19
ZION: 8-K · earnings release
ZION · 8-K · 2026-10-19
VXRT: 8-K · leadership change
VXRT · 8-K · 2026-10-19
EPAC: 8-K · debt financing
EPAC · 8-K · 2026-10-19
CURV: 8-K · leadership change
CURV · 8-K · 2026-10-19
NITO: 8-K · offering registration
NITO · 8-K · 2026-10-19
PMHS: 8-K · leadership change
PMHS · 8-K · 2026-10-19
SFBS: 8-K · earnings release
SFBS · 8-K · 2026-10-19
GCTK: 8-K · material agreement
GCTK · 8-K · 2026-10-19
SCNX: 8-K · earnings release
SCNX · 8-K · 2026-10-19
BWLP: 6-K · earnings release
BWLP · 6-K · 2026-10-19
TPST: 8-K · leadership change
TPST · 8-K · 2026-10-19
GTM: 8-K · litigation
GTM · 8-K · 2026-10-19
AGNC: 8-K · earnings release
AGNC · 8-K · 2026-10-19
ACVA: 8-K · acquisition merger
ACVA · 8-K · 2026-10-19
ZNB: 20-F · periodic report
ZNB · 20-F · 2026-10-19
THCH: 6-K · debt financing
THCH · 6-K · 2026-10-19
NIMU: 8-K · material agreement
NIMU · 8-K · 2026-10-19
CCFN: 8-K · earnings release
CCFN · 8-K · 2026-10-19
GNVR: 8-K · debt financing
GNVR · 8-K · 2026-10-19
ACRG: 8-K · leadership change
ACRG · 8-K · 2026-10-19
RUBI: 6-K · debt financing
RUBI · 6-K · 2026-10-19
RUBI: 424B5 · prospectus supplement
RUBI · 424B5 · 2026-10-19
GLASF: 6-K · earnings release
GLASF · 6-K · 2026-10-19
ZDGE: 8-K · leadership change
ZDGE · 8-K · 2026-10-19
WMT: 424B5 · prospectus supplement
WMT · 424B5 · 2026-10-19
GSK: 6-K · fda approval
GSK · 6-K · 2026-10-19
USB: 424B3 · prospectus supplement
USB · 424B3 · 2026-10-19
BWAY: 6-K · material agreement
BWAY · 6-K · 2026-10-19
MT: 6-K · ownership disclosure
MT · 6-K · 2026-10-19
ADIA: 8-K · asset sale
ADIA · 8-K · 2026-10-19
RACE: 6-K · share repurchase
RACE · 6-K · 2026-10-19
ERIC: 6-K · share repurchase
ERIC · 6-K · 2026-10-19
BAC: 424B5 · debt financing
BAC · 424B5 · 2026-10-19
CCEP: 6-K · ownership disclosure
CCEP · 6-K · 2026-10-19
FAST: 10-Q · periodic report
FAST · 10-Q · 2026-10-19
NRC: 8-K · leadership change
NRC · 8-K · 2026-10-19
DRTS: 6-K · clinical trial
DRTS · 6-K · 2026-10-19
PEBK: 8-K · earnings release
PEBK · 8-K · 2026-10-19
IINN: 6-K · other
IINN · 6-K · 2026-10-19
NRSN: 6-K · other
NRSN · 6-K · 2026-10-19
ATVK: 8-K · auditor change
ATVK · 8-K · 2026-10-19
BAFN: SCHEDULE 13D/A · ownership disclosure
BAFN · SCHEDULE 13D/A · 2026-10-19
EYPT: 8-K · clinical trial
EYPT · 8-K · 2026-10-19
CAN: 6-K · auditor change
CAN · 6-K · 2026-10-19
BBVA: 6-K · other
BBVA · 6-K · 2026-10-19
WSM: 8-K · leadership change
WSM · 8-K · 2026-10-19
WERN: 8-K · earnings release
WERN · 8-K · 2026-10-19
QSEA: 8-K · material agreement
QSEA · 8-K · 2026-10-19
BNC: 8-K · leadership change
BNC · 8-K · 2026-10-19
FRGT: 6-K · other
FRGT · 6-K · 2026-10-19
ARGX: 6-K · clinical trial
ARGX · 6-K · 2026-10-19
POM: 6-K · ticker change
POM · 6-K · 2026-10-19
CDNL: 8-K · acquisition merger
CDNL · 8-K · 2026-10-19
QZMRF: 6-K · offering registration
QZMRF · 6-K · 2026-10-19
WMT: 424B5 · debt financing
WMT · 424B5 · 2026-10-19
OSTX: 8-K · offering registration
OSTX · 8-K · 2026-10-19
LOKV: 424B3 · prospectus supplement
LOKV · 424B3 · 2026-10-19
DWTX: 8-K · offering registration
DWTX · 8-K · 2026-10-19
ATKR: 8-K · acquisition merger
ATKR · 8-K · 2026-10-19
CCEP: 6-K · share repurchase
CCEP · 6-K · 2026-10-19
EOSE: 8-K · earnings release
EOSE · 8-K · 2026-10-19
NVO: 6-K · share repurchase
NVO · 6-K · 2026-10-19
AASP: 8-K · material agreement
AASP · 8-K · 2026-10-19
HIT: 424B3 · prospectus supplement
HIT · 424B3 · 2026-10-19
STM: 6-K · share repurchase
STM · 6-K · 2026-10-19
ENLV: 6-K · other
ENLV · 6-K · 2026-10-19
LOKV: 8-K · debt financing
LOKV · 8-K · 2026-10-19
LPL: 6-K · regulatory action
LPL · 6-K · 2026-10-19
CJMB: 8-K · material agreement
CJMB · 8-K · 2026-10-19
EXE: 8-K · leadership change
EXE · 8-K · 2026-10-19
MAT: 8-K · leadership change
MAT · 8-K · 2026-10-19
XNDU: 424B3 · prospectus supplement
XNDU · 424B3 · 2026-10-19
SLN: 8-K · acquisition merger
SLN · 8-K · 2026-10-19
XNDU: 424B3 · prospectus supplement
XNDU · 424B3 · 2026-10-19
RDHL: 6-K · clinical trial
RDHL · 6-K · 2026-10-19
GLNG: 6-K · earnings release
GLNG · 6-K · 2026-10-19
INTR: 6-K · other
INTR · 6-K · 2026-10-19
DX: 8-K · earnings release
DX · 8-K · 2026-10-19
ACTU: S-1/A · offering registration
ACTU · S-1/A · 2026-10-19
XNDU: 6-K · material agreement
XNDU · 6-K · 2026-10-19
VEON: 6-K · acquisition merger
VEON · 6-K · 2026-10-19
BMOOF: 6-K · offering registration
BMOOF · 6-K · 2026-10-19
HDB: 6-K · leadership change
HDB · 6-K · 2026-10-19
HDB: 6-K · earnings release
HDB · 6-K · 2026-10-19
LEU: 8-K · acquisition merger
LEU · 8-K · 2026-10-19
RYAAY: 6-K · ownership disclosure
RYAAY · 6-K · 2026-10-19
EHGO: 6-K · amendment
EHGO · 6-K · 2026-10-19
BNTX: 6-K · clinical trial
BNTX · 6-K · 2026-10-19
GSK: 6-K · clinical trial
GSK · 6-K · 2026-10-19
OWLS: 6-K · foreign private issuer
OWLS · 6-K · 2026-10-19
PUK: 6-K · share repurchase
PUK · 6-K · 2026-10-19
‹ Prev
1
4
8
11
12
13
14
15
16
17
20
24
28
32
36
40
44
48
52
56
60
64
68
72
73
Next ›
